Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study)

References

• Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Lip GY, Lane DA. Stroke prevention in atrial fibrillation. J Am Med Assoc 2015;313:1950-62
   PubMed Web of Science ®Google Scholar
• Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014;8:789-98
   PubMed Web of Science ®Google Scholar
• De Andrés-Nogales F, Oyagüez I, Betegón-Nicolás L, et al. Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. Rev Clin Esp 2015;215:73-82
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, de Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Hernández Olmedo M, Suárez Fernández C. Progress of anticoagulation therapy in atrial fibrillation. Med Clin (Barc) 2015;145:124-30
   PubMed Web of Science ®Google Scholar
• Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107.
   PubMed Web of Science ®Google Scholar
• Mateo J. News anticoagulants and clinical practice. Rev Esp Cardiol 2013;13(SuplC):33-41
   Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017;117:209-18
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013;11:390-4
   PubMed Web of Science ®Google Scholar
• Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 2014;103:998-1005
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31-9
   PubMed Web of Science ®Google Scholar
• Márquez-Contreras E, Martell-Carlos N, Gil-Guillén V, et al. Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. Curr Med Res Opin 2016;32:2013-20
   PubMed Web of Science ®Google Scholar
• Komócsi A. Discontinuation of anticoagulant treatment: from clinical trials to medication persistence. Curr Med Res Opin 2015;31:1841-4
   PubMed Web of Science ®Google Scholar
• Garkina SV, Vavilova TV, Lebedev DS, et al. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol 2016;13:807-10
   PubMedGoogle Scholar
• Márquez-Contreras E, Gil-Guillén VF, De La Figuera-Von Wichmann M, et al. Do patients with high vascular risk take antihypertensive medication correctly? Rev Esp Cardiol 2012;65:544-50
   PubMed Web of Science ®Google Scholar
• Lee PY, Han SY, Miyahara RK. Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care. Am J Health Syst Pharm 2013;70:1154-61
   PubMed Web of Science ®Google Scholar
• Clarkesmith DE, Pattison HM, Khaing PH, et al. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 2017;4:CD008600
   PubMed Web of Science ®Google Scholar
• De Schryver EL, van Gijn J, Kappelle LJ, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. Neurology 2005;252:1316-21
   Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
   PubMed Web of Science ®Google Scholar
• Tsai K, Erickson SC, Yang J, et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013;19:e325-32
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
   PubMed Web of Science ®Google Scholar
• Cutler TW, Chuang A, Huynh TD, et al. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Spec Pharm 2014;20:1028-34
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjøth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504
   PubMed Web of Science ®Google Scholar
• Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. J Am Med Assoc 2015;313:1443-50
   PubMed Web of Science ®Google Scholar
• Paquette M, Riou França L, Teutsch C, et al. Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. J Am Coll Cardiol 2017;70:1573-83
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ebertz F, Förster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015;113:1247-57
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrilation. Curr Med Res Opin 2015;31:1831-40
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015;31:1889-95
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013–2014 data. J Manag Care Spec Pharm 2017;3:958-67
   Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol 2016;212:171-3
   PubMed Web of Science ®Google Scholar
• Potpara TS, Boriani G, Lip GYH. Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. Curr Med Res Opin 2017;33:1175-7
   PubMed Web of Science ®Google Scholar
• Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord 2017;17:236
   PubMed Web of Science ®Google Scholar
• Rubboli A. Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Curr Med Res Opin 2015;31:1845-7
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Peacock WF, Fields LE, et al. Association between once and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol 2016;215:11-13
   PubMed Web of Science ®Google Scholar
• Maura G, Pariente A, Alla F, et al. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf 2017;26:1367-77
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, et al. Intervenciones para mejorar la adherencia a la medicación (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.)
   Google Scholar
• Van Onzenoort HA, Verberk WJ, Kessels AG, et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. Am J Hypertens 2010;23:149-54
   PubMed Web of Science ®Google Scholar
• Baulmann J, Düsing R, Vetter H, et al. Therapy resistant hypertension-significance of electronic compliance monitoring. Dtsch Med Wochenschr 2002;127:2379-82
   PubMed Web of Science ®Google Scholar